BIOSIMILAR RED TAPE ELIMINATION ACT (S2305): Weakening FDA Regulatory Standards for Biosimilars, Undermining Physician Confidence and Jeopardizing Patient Health, 31 October 2024
INTERCHANGEABILITY DESIGNATION FOR BIOSIMILARS: Ensuring Continuity of Patient Care: Upholding Interchangeability Status for Biosimilars, 30 November 2023
• ‘contact us for the webinar speakers’ presentations
MEDICARE DRUG PRICE NEGOTIATIONS: impact on healthcare development and patient access to medicines, 26 July 2023
GaBI Journal is an independent and peer reviewed academic journal. GaBI Journal encompasses all aspects of generic and biosimilar medicines development and use, from fundamental research up to clinical application and policies.